Clinical Trial Search

Primary: The Primary Endpoint is the Actual Number of Subjects That Successfully Achieve Abstinence From Cocaine During the Last Three Weeks of Treatment in the "Pre-qualified…

Primary: Endothelin-1 Levels — 2.15; 2.063; 1.956 pg/ml

Primary: Number of Participants Who Were Cocaine Abstinent as Assessed by Urine Screening (Measure of Treatment Efficacy) — 3; 3; 6 Participants

Primary: Proportion of Cocaine Use Days — 0.122; 0.209 cocaine use days — p== 0.021

Primary: Cocaine Use Over Time — 0.01; 0.007; -0.01; 0.007 slope (change in prob of coc-pos utox/d) — p=<0.05

Primary: the Adult ADHD Rating Scale (AARS) (30% Reduction) — 50 percent of participants

Primary: Feasibility as Assessed by Number of Participants Who Completed Treatment — 3 Participants

Primary: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) - Heart Rate — 7.8; 4.96 beats per minute

Primary: Longest Duration of Abstinence From Cocaine — 4.14; 6.64; 6.93 weeks — p=.01

Primary: Cocaine Use Days as Measured by Self-report, Corroborated by Thrice-weekly Urine Drug Screens — 6.6; 7.2; 7.7 days of cocaine use

Primary: Regional Availability of Metabotropic Glutamate Type-5 Receptors (mGluR5) — 36.48; 32.19; 25.67; 22.41 mL*cm^3 — p=0.035

Primary: Cocaine Self-administration — 0; 0; 0; 2.2 Number of doses purchased

Primary: The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative — 0.06; 0.94; 0.75; 0.88 cocaine choices

Primary: Cocaine Self-administration — 2.5; 4.8 cocaine choices/participant

Primary: The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative — 2.75; 1.38; 1.38; 4.75 cocaine choices

Primary: Cocaine-positive Urine Results — 86.5; 92.4 percentage of BE urine tests

Primary: Percent Days Abstinent From Cocaine - Self Report — 72.9; 72.9; 59.3 percentage of days — p=.10

Primary: % Cocaine-Negative Urine Specimens Per Participant — 42.2; 59.1; 51.0 % negative specimens per participant — p=0.177

Primary: Craving Change in Stress and Cue Relative to Neutral — 3.035; -0.486; 3.959; 0.031 score on a scale — p=<.001

Primary: Three Weeks of Continuous Cocaine Abstinence as Measured by Urine Toxicology and Self Report Based on Time Line Follow Back — 13; 7 participants — p==.05

Primary: Change in Cocaine Use by Self Report — 72.2; 79.2; 91.1; 69.6 percentage of days abstinent

Primary: Mean Percentage of Cocaine-positive Urines Over Course of 12 Week Treatment in Subgroup Achieving Abstinence at Baseline — 31; 28; 47; 35 Mean % of cocaine-positive urines

Primary: Last Three Weeks of Cocaine Abstinence Based on Urine Toxicology Results and Self Reported Use — 7; 18; 30 percentage of participants

Primary: Percentage of Cocaine-positive Urines — 67.6; 69 percentage of cocaine-positive urines

Primary: Cocaine Use Determined by Urine Analysis — 62.50; 50.00 percentage of participants no cocaine — p=.4637

Primary: Functional Connectivity Between Corticolimbic Brain Regions During Acute Social Stress — .011; .012; .043; .0008 Arbitrary units

Primary: Number of Participants Who Are Cocaine Abstinent During the Last 2 Weeks of Treatment (Weeks 8-9), as Assessed by Urine Test — 0; 4; 2 Participants

Primary: Three Weeks of Cocaine Abstinence at End of Study — 9; 0 Participants

Primary: Reinforcing Effects of Cocaine — 1.3; 5.0; 8.3; 0 Number of Cocaine Choices

Primary: Cocaine Safety in Subjects Receiving Donepezil — 0; 2 Participants with an Adverse Event